Table 2. Univariate and multivariate logistic analyses to identify factors associated with NAT insensitivity.

Factor	Univariate analysis			Multivariate analysis
	OR (95% CI)	P		OR (95% CI)	P
NAT, neoadjuvant therapy; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; OR, odds ratio; 95% CI, 95% confidence interval.
T3/T4 vs. T0/T1/T2	1.706 (0.968−3.005)	0.065		1.659 (0.906−3.038)	0.101
Stage: III vs. II	1.708 (0.883−3.303)	0.112		1.420 (0.706−2.855)	0.325
HR+ vs. HR−	1.868 (1.050−3.323)	0.033		1.677 (0.924−3.403)	0.089
HER2 2+/FISH+ vs. HER2 3+	1.976 (1.046−3.733)	0.036		1.797 (0.915−3.530)	0.089
Monotherapy vs. dual-therapy	2.114 (1.229−3.638)	0.007		2.006 (1.153−3.489)	0.014